Lyell Immunopharma, Inc.

LYEL

Lyell Immunopharma, Inc.

LYEL

Insider Sentiment (TTM):

Last Purchase:2026-03-06Last Sale:2026-06-10Shares Purchased (TTM):976,180Shares Sold (TTM):15,931

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:11,811,307Shares Outstanding:21,876,000Institutional Ownership Pct.:53.99%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	73	91	60	124	99	120	106	100	133	126	146	286
Marketable Securities Current	131	163	187	196	178	181	265	340	358	401	401	289
Prepaid Expense And Other Assets Current	9	13	14	9	5	8	9	9	9	8	8	11
Assets Current	214	267	261	328	282	309	380	450	500	534	555	587
Restricted Cash Noncurrent	2	2	2	2	2	2	2	0	0	0	0	0
Marketable Securities Noncurrent	24	7	0	0	20	29	13	20	0	0	17	23
Other Investments	19	19	19	19	19	19	19	19	19	19	32	32
Property Plant And Equipment Net	31	33	35	37	39	44	48	88	93	98	103	108
Operating Lease Right Of Use Asset	17	18	19	20	21	24	25	37	38	39	40	41
Other Assets Noncurrent	6	5	5	3	3	3	5	5	4	4	4	4
Assets	311	351	340	408	385	430	491	619	654	694	750	795
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	5	3	3	3	4	5	4	4	5	5	4
Accrued Liabilities And Other Liabilities	36	31	47	29	28	31	41	29	26	25	28	30
Asset Acquisition Contingent Consideration Liabili…	-	-	0	0	6	6	8	-	-	-	0	-
Liabilities Current	40	37	49	32	37	41	54	34	31	32	35	35
Operating Lease Liability Noncurrent	37	39	42	44	47	49	51	51	53	55	57	59
Other Liabilities Noncurrent	1	1	1	3	3	3	3	4	3	4	4	4
Liabilities	77	77	92	79	87	93	108	89	88	91	95	97
Stockholders Equity Inclu…
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,922	1,917	1,868	1,808	1,739	1,734	1,728	1,683	1,675	1,666	1,657	1,648
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	0	0	0	1	-0	-0	-0	-1
Retained Earnings Accumulated Deficit	-1,688	-1,644	-1,620	-1,479	-1,440	-1,397	-1,345	-1,153	-1,109	-1,063	-1,002	-949
Stockholders Equity	234	274	248	329	299	337	383	531	567	603	655	698
Liabilities And Stockholders Equity	311	351	340	408	385	430	491	619	654	694	750	795
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	500	500	500	500	500	500	500	500	500	500	500	500
Common Stock Shares Issued	23	23	21	19	15	15	15	13	13	13	13	13
Shares Outstanding	23	23	21	19	15	15	15	13	13	13	13	13
Stockholders Equity Note Stock Split Conversion Ra…	-	-	-	-	0	-	-	-	-	-	-	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-16.88%	-44.32%	-39.42%	-	-	-	-	-	-	-	-	-
2025	57.53%	19.63%	36.05%	14.95%	67.93%	57.62%	43.22%	64.38%	36.13%	-14.39%	-15.92%	-30.05%
2024	9.06%	-42.91%	-35.43%	2.84%	7.09%	-34.26%	-22.54%	-46.72%	-50.41%	-30.18%	-30.78%	-34.38%
2023	-	-	-	-2.50%	-38.75%	-34.58%	-15.11%	-13.78%	-7.56%	-32.39%	-21.48%	-3.52%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.36	7.23	5.28	10.30	7.65	7.49	7.06	13.43	16.19	16.51	16.07	16.74
Quick Ratio	5.12	6.88	5.00	10.03	7.50	7.30	6.89	13.15	15.90	16.27	15.82	16.41
Working Capital	173.67M	230.36M	211.53M	296.32M	245.31M	267.89M	325.81M	416.53M	468.95M	501.81M	520.17M	551.79M
Leverage & Debt
Debt to Equity	0.33	0.28	0.37	0.24	0.29	0.28	0.28	0.17	0.15	0.15	0.15	0.14
Interest Coverage TTM	-24.85	-22.46	-20.60	-22.38	-19.76	-17.08	-14.91	-8.28	-8.40	-9.31	-10.53	-10.21
Debt Ratio	0.25	0.22	0.27	0.19	0.22	0.22	0.22	0.14	0.13	0.13	0.13	0.12
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05
Per Share Metrics
Diluted EPS TTM	-10.64	-11.26	-16.06	-17.83	-22.40	-22.67	-26.23	-15.92	-16.47	-17.96	-18.70	-15.13
Free Cash Flow Per Share TTM	-6.44	-6.15	-8.83	-6.06	-7.92	-11.91	-12.46	-12.19	-12.45	-12.64	-13.26	-13.57
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-949,981.48%	-826,767.74%	-748,344.44%	-836,358.54%	-593,598.33%	-554,687.69%	-588,122.95%	-344,628.57%	-417,870.37%	-352,980.88%	-190,006.15%	-417.05%
Net Profit Margin TTM	-920,285.19%	-794,858.06%	-762,355.56%	-794,292.68%	-552,328.33%	-514,649.23%	-562,285.25%	-323,792.06%	-389,368.52%	-335,794.12%	-180,486.15%	-391.93%
Growth Metrics
Net Revenue Growth (1Y)	-55.00%	-52.31%	-40.98%	-34.92%	11.11%	-4.41%	-53.08%	-99.87%	-99.89%	-99.92%	-99.85%	16.69%
Net Income Growth (1Y)	-25.02%	-26.34%	-19.98%	59.65%	57.61%	46.50%	46.18%	7.31%	0.36%	25.51%	28.13%	-39.36%
EPS Growth (1Y)	-52.53%	-50.32%	-38.80%	11.99%	36.06%	26.22%	40.32%	5.22%	-1.68%	23.21%	26.14%	-40.08%
Valuation Metrics
P/E TTM	-1.32	-1.78	-1.92	-0.91	-0.39	-0.47	-0.49	-1.73	-1.76	-2.48	-2.08	-1.94
P/B TTM	1.40	1.60	2.12	0.90	0.44	0.47	0.44	0.67	0.65	0.94	0.74	0.53
P/S TTM	12,157.93	14,155.89	14,614.52	7,235.91	2,179.50	2,442.52	2,743.40	5,614.19	6,857.96	8,337.97	3,745.44	7.62
Market Cap	328.26M	438.83M	526.12M	296.67M	130.77M	158.76M	167.35M	353.69M	370.33M	566.98M	486.91M	369.44M
Enterprise Value	253.69M	346.48M	464.36M	171.51M	30.38M	36.75M	60.06M	253.11M	236.62M	441.05M	340.98M	82.94M
Calculated Values
Free Cash Flow TTM	-150.36M	-134.58M	-150.96M	-110.71M	-117.17M	-175.80M	-162.86M	-156.23M	-159.01M	-160.68M	-166.38M	-170.57M
Net Debt	-74.57M	-92.36M	-61.77M	-125.16M	-100.39M	-122.02M	-107.29M	-100.59M	-133.71M	-125.94M	-145.93M	-286.50M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-10Sale

Owner: Shook, David

Title: Chief Medical Officer

Shares: 1,977

Price/Share: $12.64

Value: $24,989.28

Shares Owned: 20,923

Relationship: Officer

Ownership: Direct

2026-05-11Sale

Owner: Seely, Lynn

Title: President and CEO

Shares: 388

Price/Share: $18.91

Value: $7,337.08

Shares Owned: 73,878

Relationship: Director,Officer

Ownership: Direct

2026-05-11Sale

Owner: Hill, Stephen J.

Title: Chief Operating Officer

Shares: 89

Price/Share: $18.92

Value: $1,683.88

Shares Owned: 17,894

Relationship: Officer

Ownership: Direct

2026-05-11Sale

Owner: Lee, Gary K.

Title: Chief Scientific Officer

Shares: 130

Price/Share: $18.92

Value: $2,459.60

Shares Owned: 17,808

Relationship: Officer

Ownership: Direct

2026-05-11Sale

Owner: Bulis, Veronica Sanchez

Title: VP, Corporate Controller

Shares: 217

Price/Share: $18.91

Value: $4,103.47

Shares Owned: 15,420

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-10	Shook, David	Officer	Chief Medical Officer	Direct	Sale	1,977	12.64	$24,989.28	20,923	4
2026-05-11	Seely, Lynn	Director,Officer	President and CEO	Direct	Sale	388	18.91	$7,337.08	73,878	4
2026-05-11	Hill, Stephen J.	Officer	Chief Operating Officer	Direct	Sale	89	18.92	$1,683.88	17,894	4
2026-05-11	Lee, Gary K.	Officer	Chief Scientific Officer	Direct	Sale	130	18.92	$2,459.60	17,808	4
2026-05-11	Bulis, Veronica Sanchez	Officer	VP, Corporate Controller	Direct	Sale	217	18.91	$4,103.47	15,420	4
2026-03-06	Berns, Paul L, Burow Kris…	TenPercentOwner	-	Indirect	Purchase	488,090	25.61	$12,499,984.90	1,426,528	4
2026-03-06	Arch, Venture Partners Ix…	TenPercentOwner	-	Indirect	Purchase	488,090	25.61	$12,499,984.90	1,426,528	4
2026-02-11	Seely, Lynn	Director,Officer	President and CEO	Direct	Sale	7,455	23.39	$174,372.45	74,266	4
2026-02-11	Lee, Gary K.	Officer	Chief Scientific Officer	Direct	Sale	1,671	23.39	$39,084.69	16,938	4
2026-02-11	Hill, Stephen J.	Officer	Chief Operating Officer	Direct	Sale	1,236	23.39	$28,910.04	17,795	4
2026-02-10	Lee, Gary K.	Officer	Chief Scientific Officer	Direct	Sale	147	23.12	$3,398.64	18,609	4
2026-02-10	Seely, Lynn	Director,Officer	President and CEO	Direct	Sale	438	23.12	$10,126.56	81,721	4
2026-02-10	Bulis, Veronica Sanchez	Officer	VP, Corporate Controller	Direct	Sale	254	23.12	$5,872.48	15,637	4
2026-02-10	Hill, Stephen J.	Officer	Chief Operating Officer	Direct	Sale	109	23.12	$2,520.08	19,031	4
2025-12-30	Bulis, Veronica Sanchez	Officer	VP, Corporate Controller	Direct	Sale	936	32.32	$30,251.52	7,141	4
2025-11-10	Hill, Stephen J.	Officer	Chief Operating Officer	Direct	Sale	95	16.12	$1,531.40	15,750	4
2025-11-10	Seely, Lynn	Director,Officer	President and CEO	Direct	Sale	412	16.11	$6,637.32	67,159	4
2025-11-10	Lee, Gary K.	Officer	Chief Scientific Officer	Direct	Sale	138	16.16	$2,230.08	15,366	4
2025-11-10	Bulis, Veronica Sanchez	Officer	VP, Corporate Controller	Direct	Sale	239	16.10	$3,847.90	9,213	4
2025-08-21	Hill, Stephen J.	Officer	Chief Operating Officer	Direct	Sale	1,004	10.54	$10,582.16	15,845	4
2025-08-21	Lee, Gary K.	Officer	Chief Scientific Officer	Direct	Sale	1,453	10.54	$15,314.62	15,504	4
2025-08-21	Newton, Charles W.	Officer	Chief Financial Officer	Direct	Sale	1,453	10.54	$15,314.62	15,306	4
2025-08-21	Seely, Lynn	Director,Officer	President and CEO	Direct	Sale	7,257	10.54	$76,488.78	67,571	4
2025-08-12	Lee, Gary K.	Officer	Chief Scientific Officer	Direct	Sale	136	10.34	$1,406.24	8,957	4
2025-08-12	Seely, Lynn	Director,Officer	President and CEO	Direct	Sale	406	10.34	$4,198.04	34,828	4
2025-08-12	Hill, Stephen J.	Officer	Chief Operating Officer	Direct	Sale	94	10.34	$971.96	8,849	4
2025-08-12	Newton, Charles W.	Officer	Chief Financial Officer	Direct	Sale	136	10.34	$1,406.24	8,759	4
2025-03-31	Brawley, Otis W	Director	-	Direct	Purchase	35,640	0.56	$19,958.40	35,640	4
2025-03-21	Ramachandra, Sumant	Director	-	Indirect	Purchase	200,000	0.58	$116,000.00	200,000	4
2025-03-17	Newton, Charles W.	Officer	Chief Financial Officer	Indirect	Purchase	200,000	0.56	$112,000.00	200,000	4
2025-03-14	Klausner, Richard	Director	-	Indirect	Purchase	158,000	0.60	$94,800.00	843,365	4
2025-03-14	Seely, Lynn	Director,Officer	President and CEO	Direct	Purchase	175,000	0.61	$106,750.00	712,500	4
2023-08-15	Klausner, Richard	Director	-	Indirect	Sale	58,020	2.28	$132,285.60	930,880	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

53.99%

Inst. Shares: 11,811,307

Shares Outstanding: 21,876,000

2025-12-31

66.56%

Inst. Shares: 11,376,970

Shares Outstanding: 17,093,000

2025-09-30

51.81%

Inst. Shares: 9,463,806

Shares Outstanding: 18,268,000

2025-06-30

43.82%

Inst. Shares: 6,482,452

Shares Outstanding: 14,793,000

2025-03-31

49.04%

Inst. Shares: 7,236,373

Shares Outstanding: 14,755,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	11,811,307	21,876,000	53.99%
2025-12-31	11,376,970	17,093,000	66.56%
2025-09-30	9,463,806	18,268,000	51.81%
2025-06-30	6,482,452	14,793,000	43.82%
2025-03-31	7,236,373	14,755,000	49.04%
2024-12-31	7,128,906	13,074,000	54.53%
2024-09-30	5,973,899	12,815,000	46.62%
2024-06-30	6,255,851	12,770,000	48.99%
2024-03-31	6,230,422	12,712,600	49.01%
2023-12-31	6,166,989	12,549,150	49.14%
2023-09-30	5,754,259	12,565,900	45.79%
2023-06-30	5,674,213	12,510,200	45.36%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Lyell Immunopharma, Inc. (LYEL) — SEC Financial Statements & Analysis

Lyell Immunopharma, Inc. (LYEL) is a pharmaceutical preparations company, incorporated in DE. Lyell Immunopharma, Inc. trades on Nasdaq as: LYEL. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Lyell Immunopharma, Inc. reported a -55.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.33x, a Price-to-Sales (P/S) ratio of 12157.93x (TTM), a Price-to-Book (P/B) ratio of 1.40x (TTM), at a market cap of $328.26M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -55.00%
Debt To Equity: 0.33x
P/S TTM: 12157.93x
P/B TTM: 1.40x
Market Cap: $328.26M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Lyell Immunopharma, Inc. in?

Lyell Immunopharma, Inc. (LYEL) operates in the Pharmaceutical Preparations industry.

What is LYEL's market cap?

Lyell Immunopharma, Inc. (LYEL) has a market capitalization of $328.26M as of 2026-06-30.

What exchange does LYEL trade on?

Lyell Immunopharma, Inc. (LYEL) trades on the Nasdaq.

Where is Lyell Immunopharma, Inc. incorporated?

Lyell Immunopharma, Inc. is incorporated in DE.